Report preliminary objective response rate data for PDS0101 plus KEYTRUDA trial
Deadline passed; outcome being checked
- Announced
- 11 Mar 2021
- Due
- 31 Mar 2022
- Status
- Checking
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Preliminary data – Q4 2021/Q1 2022, ORR in first 20 patients (efficacy in 7 of 38 required to enroll all 96 patients)”
What we found
The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Preliminary ORR data from PDS0101 and KEYTRUDA head and neck trial
- Target
- 20 patients
- In the company’s control
- High
- Specificity
- Medium
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you PDS Biotechnology Corp? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-PDSB-025614 · Corrections policy